Fate Therapeutics Q3 EPS $(0.4) Misses $(0.38) Estimate, Sales $2.4M Beat $1.79M Estimate

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.4) per share which missed the analyst consensus estimate of $(0.38) by 5.26 percent. This is a 29.03 percent decrease over losses of $(0.31) per share from

Benzinga · 11/05/2019 21:10

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.4) per share which missed the analyst consensus estimate of $(0.38) by 5.26 percent. This is a 29.03 percent decrease over losses of $(0.31) per share from the same period last year. The company reported quarterly sales of $2.4 million which beat the analyst consensus estimate of $1.79 million by 34.08 percent. This is a 133.92 percent increase over sales of $1.026 million the same period last year.